Your browser doesn't support javascript.
loading
Germline MBD4 deficiency causes a multi-tumor predisposition syndrome.
Palles, Claire; West, Hannah D; Chew, Edward; Galavotti, Sara; Flensburg, Christoffer; Grolleman, Judith E; Jansen, Erik A M; Curley, Helen; Chegwidden, Laura; Arbe-Barnes, Edward H; Lander, Nicola; Truscott, Rebekah; Pagan, Judith; Bajel, Ashish; Sherwood, Kitty; Martin, Lynn; Thomas, Huw; Georgiou, Demetra; Fostira, Florentia; Goldberg, Yael; Adams, David J; van der Biezen, Simone A M; Christie, Michael; Clendenning, Mark; Thomas, Laura E; Deltas, Constantinos; Dimovski, Aleksandar J; Dymerska, Dagmara; Lubinski, Jan; Mahmood, Khalid; van der Post, Rachel S; Sanders, Mathijs; Weitz, Jürgen; Taylor, Jenny C; Turnbull, Clare; Vreede, Lilian; van Wezel, Tom; Whalley, Celina; Arnedo-Pac, Claudia; Caravagna, Giulio; Cross, William; Chubb, Daniel; Frangou, Anna; Gruber, Andreas J; Kinnersley, Ben; Noyvert, Boris; Church, David; Graham, Trevor; Houlston, Richard; Lopez-Bigas, Nuria.
Afiliação
  • Palles C; Institute of Cancer and Genomic Sciences, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
  • West HD; Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff University, School of Medicine, Cardiff, UK.
  • Chew E; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
  • Galavotti S; Institute of Cancer and Genomic Sciences, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
  • Flensburg C; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia.
  • Grolleman JE; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 Nijmegen, the Netherlands.
  • Jansen EAM; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 Nijmegen, the Netherlands.
  • Curley H; Institute of Cancer and Genomic Sciences, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
  • Chegwidden L; Institute of Cancer and Genomic Sciences, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
  • Arbe-Barnes EH; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Lander N; Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff University, School of Medicine, Cardiff, UK.
  • Truscott R; Institute of Medical Genetics, Division of Cancer and Genetics, Cardiff University, School of Medicine, Cardiff, UK.
  • Pagan J; Molecular Genetics Laboratory, South East Scotland Genetic Service, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, UK.
  • Bajel A; Peter MacCallum Cancer Center and Royal Melbourne Hospital, Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.
  • Sherwood K; Edinburgh Cancer Research Centre, IGMM, University of Edinburgh, Crewe Road, Edinburgh EH4 2XR, UK.
  • Martin L; Institute of Cancer and Genomic Sciences, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
  • Thomas H; St Mark's Hospital, Imperial College London, London, UK.
  • Georgiou D; Genomic Medicine, Imperial College Healthcare Trust and North West Thames Regional Genetics Service, Northwick Park, Harrow, UK.
  • Fostira F; Molecular Diagnostics Laboratory, NCSR Demokritos, Athens, Greece.
  • Goldberg Y; Raphael Recanati Genetic Institute, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Adams DJ; Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
  • van der Biezen SAM; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 Nijmegen, the Netherlands.
  • Christie M; Walter and Eliza Hall Institute of Medical Research, Parkville, VIC 3052, Australia; Colorectal Oncogenomics Group, Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Parkville, VIC, Australia.
  • Clendenning M; Colorectal Oncogenomics Group, Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Parkville, VIC, Australia; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.
  • Thomas LE; Institute of Life Sciences, Swansea University, Swansea SA28PP, UK.
  • Deltas C; Center of Excellence in Biobanking and Biomedical Research and Molecular Medicine Research Center, University of Cyprus Medical School, Nicosia, Cyprus.
  • Dimovski AJ; Center for Biomolecular Pharmaceutical Analyzes, UKIM Faculty of Pharmacy, 1000 Skopje, Republic of Macedonia.
  • Dymerska D; Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Lubinski J; Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, 70-111 Szczecin, Poland.
  • Mahmood K; Colorectal Oncogenomics Group, Department of Clinical Pathology, Melbourne Medical School, The University of Melbourne, Parkville, VIC, Australia; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, Australia.
  • van der Post RS; Department of Pathology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 Nijmegen, the Netherlands.
  • Sanders M; Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • Weitz J; Department of Surgical Research, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.
  • Taylor JC; Oxford NIHR Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Turnbull C; Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK.
  • Vreede L; Department of Human Genetics, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 Nijmegen, the Netherlands.
  • van Wezel T; Department of Pathology, Leiden University Medical Center, 2300 Leiden, the Netherlands.
  • Whalley C; Institute of Cancer and Genomic Sciences, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
  • Arnedo-Pac C; Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Caravagna G; Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK.
  • Cross W; Cancer Institute, University College London, 72 Huntley Street, London WC1E 6BT, UK.
  • Chubb D; Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK.
  • Frangou A; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Gruber AJ; Manchester Interdisciplinary Biocentre, University of Manchester, Manchester M1 7DN, UK.
  • Kinnersley B; Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK.
  • Noyvert B; Institute of Cancer and Genomic Sciences, College of Medical and Dental Science, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.
  • Church D; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
  • Graham T; Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Houlston R; Institute of Cancer Research, Cotswold Road, Sutton, Surrey SM2 5NG, UK.
  • Lopez-Bigas N; Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, Barcelona, Spain.
Am J Hum Genet ; 109(5): 953-960, 2022 05 05.
Article em En | MEDLINE | ID: mdl-35460607
ABSTRACT
We report an autosomal recessive, multi-organ tumor predisposition syndrome, caused by bi-allelic loss-of-function germline variants in the base excision repair (BER) gene MBD4. We identified five individuals with bi-allelic MBD4 variants within four families and these individuals had a personal and/or family history of adenomatous colorectal polyposis, acute myeloid leukemia, and uveal melanoma. MBD4 encodes a glycosylase involved in repair of GT mismatches resulting from deamination of 5'-methylcytosine. The colorectal adenomas from MBD4-deficient individuals showed a mutator phenotype attributable to mutational signature SBS1, consistent with the function of MBD4. MBD4-deficient polyps harbored somatic mutations in similar driver genes to sporadic colorectal tumors, although AMER1 mutations were more common and KRAS mutations less frequent. Our findings expand the role of BER deficiencies in tumor predisposition. Inclusion of MBD4 in genetic testing for polyposis and multi-tumor phenotypes is warranted to improve disease management.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Uveais / Neoplasias Colorretais / Polipose Adenomatosa do Colo Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Uveais / Neoplasias Colorretais / Polipose Adenomatosa do Colo Idioma: En Ano de publicação: 2022 Tipo de documento: Article